$GH News

BTIG Maintains Buy on Guardant Health, Raises Price Target to $190

Guggenheim Maintains Buy on Guardant Health, Raises Price Target to $160

Bernstein Reinstates Outperform on Guardant Health, Announces $175 Price Target

Barclays Maintains Overweight on Guardant Health, Raises Price Target to $150

Guardant Health Inc. (NASDAQ:GH) Shines as a Top Minervini Trend Template and High Growth Momentum Pick

RBC Capital Initiates Coverage On Guardant Health with Outperform Rating, Announces Price Target of $185

Guardant Health Says FDA Approves Guardant360 CDx As Companion Diagnostic For Boehringer Ingelheim's HERNEXEOS

Mizuho Maintains Outperform on Guardant Health, Raises Price Target to $175

Guardant Health, Inc. (GH) Presents at 46th Annual William Blair Growth Stock Conference - Slideshow

Goldman Sachs Initiates Coverage On Guardant Health with Buy Rating, Announces Price Target of $165

Wolfe Research Assumes Guardant Health at Outperform, Announces Price Target of $150

Evercore ISI Group Upgrades Guardant Health to Outperform, Raises Price Target to $160

Testing & Diagnostics Services Stocks Q1 Earnings: Guardant Health (NASDAQ:GH) Firing on All Cylinders

Guardant Health To Present 38 Abstracts, As Well As One Oral Presentation In Partnership With Pfizer, Showcasing Advances In Methylation-Based Tumor Classification And Liquid Biopsy Technology At ASCO Annual Meeting 2026

BTIG Maintains Buy on Guardant Health, Raises Price Target to $160

American Cancer Society Recommends Guardant Health’s Shield Blood Test in Updated Colorectal Cancer Screening Guidelines

Guardant Health Says Its FDA-Approved Shield Blood Test Is Now Included In Updated American Cancer Society Colorectal Cancer Screening Guidelines

BTIG Maintains Buy on Guardant Health, Raises Price Target to $155

A Look At Guardant Health’s Valuation After Its Recent Share Price Surge

Guardant Health (GH) Is Up 25.3% After FDA Clears First Genomic‑Epigenomic Liquid Biopsy Panel – Has The Bull Case Changed?